News

EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...
Novo Nordisk's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
India Today2d
European drugs regulator flags rare eye risk with Ozempic
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Devdiscourse6h
Health News: Measles Outbreak Status, Omada IPO Surge, and More
Recent health updates include Texas experiencing a lull in measles cases, Omada’s successful Nasdaq debut, no bird flu ...
Consilium4d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...
BioSpace2d
EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
Morningstar3d
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...